Virtus ETF Advisers’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-3,362
| Closed | -$343K | – | 483 |
|
|
2023
Q2 | $343K | Buy |
3,362
+488
| +17% | +$46.2K | 0.2% | 162 |
|
|
2023
Q1 | $261K | Sell |
2,874
-1,101
| -28% | -$64.6K | 0.14% | 273 |
|
|
2022
Q4 | $151K | Buy |
3,975
+371
| +10% | +$12.8K | 0.08% | 342 |
|
|
2022
Q3 | $91K | Buy |
3,604
+25
| +0.7% | +$693 | 0.04% | 425 |
|
|
2022
Q2 | $109K | Sell |
3,579
-1,785
| -33% | -$53.3K | 0.04% | 411 |
|
|
2022
Q1 | $176K | Sell |
5,364
-320
| -6% | -$9.5K | 0.08% | 207 |
|
|
2021
Q4 | $150K | Buy |
5,684
+4,198
| +283% | +$325K | 0.06% | 350 |
|
|
2021
Q3 | $150K | Sell |
1,486
-74
| -5% | -$8.67K | 0.07% | 342 |
|
|
2021
Q2 | $221K | Sell |
1,560
-977
| -39% | -$110K | 0.09% | 272 |
|
|
2021
Q1 | $253K | Buy |
2,537
+39
| +2% | +$4.55K | 0.11% | 286 |
|
|
2020
Q4 | $309K | Buy |
2,498
+605
| +32% | +$79.5K | 0.13% | 200 |
|
|
2020
Q3 | $184K | Sell |
1,893
-253
| -12% | -$31.6K | 0.1% | 305 |
|
|
2020
Q2 | $335K | Buy |
2,146
+408
| +23% | +$62K | 0.16% | 279 |
|
|
2020
Q1 | $251K | Sell |
1,738
-254
| -13% | -$49K | 0.1% | 250 |
|
|
2019
Q4 | $407K | Sell |
1,992
-1,109
| -36% | -$202K | 0.07% | 248 |
|
|
2019
Q3 | $249K | Sell |
3,101
-172
| -5% | -$14.6K | 0.05% | 214 |
|
|
2019
Q2 | $309K | Sell |
3,273
-1,123
| -26% | -$97K | 0.07% | 203 |
|
|
2019
Q1 | $376K | Sell |
4,396
-560
| -11% | -$46.5K | 0.8% | 40 |
|
|
2018
Q4 | $278K | Sell |
4,956
-6,983
| -58% | -$426K | 0.05% | 138 |
|
|
2018
Q3 | $976K | Sell |
11,939
-8,545
| -42% | -$602K | 0.1% | 51 |
|
|
2018
Q2 | $716K | Sell |
20,484
-9,604
| -32% | -$293K | 0.63% | 93 |
|
|
2018
Q1 | $617K | Buy |
30,088
+16,171
| +116% | +$416K | 0.54% | 105 |
|
|
2017
Q4 | $394K | Buy |
13,917
+992
| +8% | +$27.7K | 0.49% | 55 |
|
|
2017
Q3 | $402K | Buy |
12,925
+1,182
| +10% | +$35.5K | 0.05% | 110 |
|
|
2017
Q2 | $372K | Sell |
11,743
-1,166
| -9% | -$28.7K | 0.06% | 80 |
|
|
2017
Q1 | $292K | Buy |
12,909
+1,237
| +11% | +$30.6K | 0.05% | 139 |
|
|
2016
Q4 | $255K | Buy |
+11,672
| New | +$295K | 0.08% | 135 |
|
Other funds holding RETA
Virtus ETF Advisers's RETA Position: Q3 2023 in Review
Virtus ETF Advisers sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 3,362 shares — an estimated $343K sold.
Virtus ETF Advisers first reported a position in RETA in Q4 2016 and held it in 27 quarters. The position peaked at $976K in Q3 2018. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- Virtus ETF Advisers reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- Virtus ETF Advisers sold 3,362 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $343K.
- Virtus ETF Advisers first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2016 and held it in 27 quarters.
- Virtus ETF Advisers's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $976K in Q3 2018.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on Virtus ETF Advisers's 13F filing for Q3 2023, filed 7 Nov 2023.